Pharmaceutical & Medical
Global pharmaceutical sales were $629bn in 2007, of which around 45% was generated in the US and 9% in Japan. Europe accounted for 30% (with France, Germany, the UK and Italy the biggest markets). The Asia Pacific and Latin America regions accounted for almost 7% and 4% respectively. The biggest healthcare segment is cardiovascular, which includes treatments for high blood pressure, cholesterol and diabetes. The value of pharmaceutical sales in the CV segment was $145m in 2007. Other important sectors were neuroscience ($120m in sales), infection ($67bn), respiratory & inflammation ($48bn), cancer ($39bn), gastrointestinal ($37bn),
The World's Leading Drug Companies in 2006 by Pharmaceutical Revenues
Pfizer ($45.1bn) |
Bristol-Myers Squibb
($13.9bn) |
|
Glaxo SmithKline ($39.2bn) |
Amgen
($13.9bn) |
|
Sanofi-Aventis ($37.4bn) |
Abbott Laboratories
($12.4bn) |
|
Novartis ($29.5bn) |
Boehringer-Ingelheim
($11.0bn) |
|
AstraZeneca
($26.5bn) |
Bayer Healthcare ($9.9bn) |
|
Johnson & Johnson
($23.3bn) |
Takeda
($8.9bn) |
|
Merck & Co ($22.6bn) |
Schering-Plough
($8.6bn) |
|
Roche
($16.9bn) |
Teva
($7.8bn) |
|
Eli Lilly & Co
($16.0bn) |
Genentech
($7.6bn) |
|
Wyeth ($15.7bn) |
Schering
($7.5bn) |
Source: Pharmaceutical Executive
The World's Top 20 Prescription Drugs in 2006 by global sales
|
Lipitor $13.6bn Pfizer |
Aranesp $4.1bn Amgen
|
|
Seretide / Advair $6.1bn Glaxo SmithKline |
Rituxan / MabThera $3.9bn Roche/Genentech
|
|
Plavix / Iscover $6.1bn
BMS/Sanofi-Aventis |
Effexor $3.7bn Wyeth
|
|
Nexium $5.2bn AstraZeneca |
Protonix / Pantozol $3.6bn Wyeth
|
|
Norvasc $4.9bn Pfizer |
Singulair $3.6bn Merck & Co
|
|
Remicade $4.4bn
Johnson & Johnson/Schering-Plough
|
Seroquel $3.6bn AstraZeneca/Astellas
Pharma
|
|
Enbrel $4.4bn Amgen/Wyeth |
Prevacid / Takepron $3.4bn TAP / Takeda
|
|
Zyprexa $4.4bn Eli
Lilly |
Actos $3.3bn Takeda/Eli
Lilly |
|
Diovan $4.2bn Novartis
|
Procrit / Eprex $3.2bn Johnson
& Johnson
|
|
Risperdal $4.2bn Johnson
& Johnson |
Cozaar / Hyzaar $3.2bn Merck & Co |
Source: Med Ad News
The World's Leading OTC Heathcare Companies in 2005 by non-prescription healthcare revenues
|
Johnson & Johnson ($9.1bn) |
Pfizer ($3.9bn) |
|
Novartis ($7.3bn) |
Bayer Healthcare ($2.9bn) |
|
Glaxo SmithKline ($5.4bn) |
Wyeth ($2.5bn) |
|
Procter & Gamble ($4.5bn) |
Reckitt Benckiser / BHI ($2.3bn) |
|
Colgate-Palmolive ($4.3bn) |
Bristol-Myers Squibb ($2.2bn) |
The Top 5 US OTC Medicines in 2002 by sales
| Analgesics | Antacid | Cold Allergy Sinus |
|
private label ($453m) |
private label ($139m) |
private label ($315m) |
|
Tylenol ($318m) |
Pepcid AC ($83m) (J&J) |
Benadryl ($122m) (Pfizer) |
|
Advil ($283m) (Wyeth) |
Zantac 75 ($82m) (Pfizer) |
Claritin ($94m) (Schering-Plough) |
|
Aleve ($143m) (Bayer) |
Tums EX ($66m) (Glaxo SmithKline) |
Alka-Selzer Plus ($62m) (Bayer) |
|
Bayer ($117m) (Bayer) |
Pepcid Complete ($46m) (J &J) |
Tylenol Cold ($62m) |
|
Tylenol PM ($112m) |
Gas X ($38m) (Novartis) |
Sudafed ($55m) (Pfizer) |
Source: Grocery Headquarters 52 weeks to May 03 Food/Drug/Mass Merchandisers ex Wal-Mart
The Top
UK Pharmacy Products in 2002 by sales
Other companies profiled in Adbrands with Pharmaceutical & Medical divisions
|
Nestle |
Paras Pharmaceuticals (India) |